Jump to Section
→ Why Pediatric Apheresis Is Different
Pediatric patients undergoing apheresis face challenges that do not exist — or are far less pronounced — in adults. The combination of small total blood volume, immature organ function, limited vascular access options, and inability to communicate symptoms creates a clinical environment that demands meticulous preparation and continuous monitoring.
A 2025 analysis of 53 pediatric TPE patients at a major European center (Eichinger et al., Children, Basel) found a complication rate of 28.3%, with hypocalcemia (12.9%), hypotension (9.4%), and allergic reactions (5.9%) as the most common adverse events. Notably, 84% of patients showed clinical improvement — confirming that pediatric apheresis is both safe and effective when performed with appropriate precautions. The highest complication rates were observed in patients under 10 kg and those with pre-existing hemodynamic instability.
Critical Safety Rule: The 15% ECV/TBV Threshold
If the extracorporeal circuit volume (ECV) exceeds 15% of the patient's total blood volume (TBV), the circuit must be primed with packed red blood cells (pRBCs) before connecting the patient. Failure to prime in this scenario can cause acute hypovolemia, severe anemia, and hemodynamic collapse — particularly in neonates and infants where the circuit may represent 20–30% of TBV. This is the single most important safety check in pediatric apheresis.
1 Extracorporeal Volume (ECV) & Circuit Priming
The extracorporeal volume of an apheresis circuit (typically 155–300 mL depending on the device) is fixed regardless of patient size. In a 70 kg adult, 185 mL represents approximately 4% of TBV — well within safe limits. In a 10 kg child with a TBV of ~750 mL, the same circuit represents 25% of TBV, which is immediately life-threatening without priming.
ECV Decision Framework by Weight
Age-Based Total Blood Volume (TBV) Reference
| Age Group | TBV (mL/kg) | Example: 10 kg Patient | Spectra Optia 185 mL = % TBV |
|---|---|---|---|
| Neonate (<1 month) | 85–90 mL/kg | 875 mL | 21.1% — Prime Required |
| Infant (1–12 months) | 80 mL/kg | 800 mL | 23.1% — Prime Required |
| Child (1–12 years) | 70–75 mL/kg | 725 mL | 25.5% — Prime Required |
| Adolescent / Adult (>13 yr) | 65–70 mL/kg | 675 mL | 27.4% — Prime Required |
Priming Fluid Selection
| ECV % of TBV | Status | Priming Fluid | Volume |
|---|---|---|---|
| ≤10% | Safe | No prime required | — |
| 10–15% | Caution | 5% Albumin or Normal Saline | Match circuit ECV volume |
| >15% (Hgb adequate) | Prime Required | pRBCs (irradiated, CMV-negative preferred) | 10–15 mL/kg |
| >15% (Hgb low, <8 g/dL) | Prime Required | pRBCs + consider FFP for coagulation support | 10–15 mL/kg pRBC; FFP per coag status |
Use the ECV Safety Calculator
The ECV Safety Check Calculator on this site includes a Pediatric Mode with age-based TBV formulas (Neonate 87.5 mL/kg → Child 72.5 mL/kg → Adult Nadler formula). Enter the patient's age group, weight, and circuit type to get an instant ECV% and priming recommendation.
2 Vascular Access
Vascular access is one of the most technically challenging aspects of pediatric apheresis. Adult-sized catheters cause vessel injury in small children; undersized catheters collapse under the high flow rates required by apheresis machines (typically 30–80 mL/min). The minimum catheter size for apheresis is 7 French — smaller lumens cannot sustain adequate flow without collapsing.
Central Venous Catheter (CVC) Size by Weight
Adapted from Stanford Children's Hospital and kidney.wiki guidelines. Final selection must account for individual patient anatomy and institutional availability.
| Patient Weight | Short-Term (≤14 days) | Long-Term (>14 days) | Notes |
|---|---|---|---|
| <5 kg | 7 Fr × 10 cm (uncuffed) | No cuffed option available | Femoral or IJ access. Highest risk group. |
| 5–15 kg | 7–8 Fr (uncuffed) | 8 Fr cuffed dialysis catheter | Femoral preferred in infants for easier placement. |
| 15–30 kg | 8 Fr (cuffed or uncuffed) | 8 Fr cuffed; 9.5 Fr PowerHickman® if available | IJ preferred over femoral for long-term access. |
| 30–50 kg | 9 Fr (cuffed or uncuffed) | 9.5 Fr PowerHickman® or 12 Fr dual-lumen apheresis port† | Apheresis ports require 7–21 days post-placement before use. |
| >50 kg | 9–11 Fr (standard adult) | 12 Fr dual-lumen port or two 8 Fr single-lumen ports‡ | Standard adult protocols apply. |
† Apheresis ports can be placed in some patients <40 kg but vein size determines feasibility. ‡ Two 8 Fr single-lumen ports have effective combined lumen ~16 Fr; only suitable for patients >50 kg.
Access Site Selection
| Site | Preferred For | Advantages | Disadvantages |
|---|---|---|---|
| Internal Jugular (IJ) | Short-term; >10 kg | Lower infection risk than femoral; good flow rates | Requires sedation in young children; pneumothorax risk |
| Femoral | Infants <10 kg; emergency access | Easier placement in small children; lower pneumothorax risk | Higher infection risk; movement restriction |
| Subclavian | Older children >25 kg | Patient comfort; good long-term patency | Higher pneumothorax risk; difficult in small children |
| Peripheral IV (bilateral) | Stable patients >20 kg; Europe more common | No central line required; lower infection risk | Flow limitation; 19–20G minimum; not standard in North America |
ℹ️ Key Principle: Preserve Future Access Sites
The goal of vascular access planning in pediatrics is to provide adequate flow for the current procedure without compromising future access sites. For patients who may require repeated or long-term apheresis (e.g., CIDP, SCD), tunneled cuffed catheters or implanted ports should be considered early to protect peripheral veins.
3 Anticoagulation & Citrate Toxicity
Citrate is the standard anticoagulant for apheresis procedures. It works by chelating ionized calcium (iCa²⁺) in the extracorporeal circuit, preventing clotting. In adults, the liver rapidly metabolizes citrate, maintaining systemic calcium levels. In children — particularly neonates and infants — hepatic citrate metabolism is immature, and the ratio of citrate infused to body weight is significantly higher, creating a much greater risk of symptomatic hypocalcemia.
Prophylactic IV Calcium is Mandatory in Pediatric Apheresis
Unlike adult apheresis where calcium supplementation is often reactive (given when symptoms appear), pediatric apheresis requires prophylactic IV calcium infusion started at the beginning of the procedure. Do not wait for symptoms. Hypocalcemia in children often presents atypically — as abdominal pain, vomiting, agitation, and pallor — rather than the classic perioral tingling seen in adults. By the time classic symptoms appear, ionized calcium may already be critically low.
Pediatric Hypocalcemia Presentation (differs from adults)
| Symptom Category | Adult Presentation | Pediatric Presentation |
|---|---|---|
| Neuromuscular | Perioral tingling, hand/foot cramps, Chvostek sign | Irritability, agitation, muscle twitching, seizures |
| GI | Mild nausea | Acute abdominal pain, vomiting (often first sign) |
| Cardiovascular | Palpitations, prolonged QT | Hypotension, pallor, bradycardia |
| Behavioral | Anxiety | Crying, inconsolability, pallor — may be misinterpreted as procedure anxiety |
Anticoagulation Protocol Summary
| Anticoagulant | Typical Use | Pediatric Consideration |
|---|---|---|
| ACD-A (Citrate) | Standard for centrifugal apheresis | Reduce inlet:AC ratio to 12:1 or 11:1 in small children. Start prophylactic IV calcium gluconate at procedure start. |
| Heparin | Alternative; membrane-based procedures | Weight-based dosing (50–100 units/kg bolus). Monitor anti-Xa levels. Avoid in HIT. |
| Combined Citrate + Heparin | High-clotting-risk procedures | Reduces citrate load; may be preferred in neonates. Requires careful monitoring. |
IV Calcium Supplementation Protocol
Standard approach: Calcium gluconate 10% solution at 1–2 mL/kg/hour IV infusion throughout the procedure, titrated to maintain ionized calcium >1.0 mmol/L. Check ionized calcium at baseline, 30 minutes into procedure, and every 60 minutes thereafter. Use the Citrate Toxicity Risk Calculator to estimate citrate dose and risk level.
4 Fluid Balance
In adult apheresis, a 100–200 mL fluid balance error is clinically insignificant. In a 5 kg neonate with a TBV of ~425 mL, the same error represents 25–50% of circulating volume — a potentially catastrophic discrepancy. Meticulous, real-time fluid balance tracking is non-negotiable in pediatric apheresis.
Fluid Balance Principles
| Principle | Clinical Rationale | Action |
|---|---|---|
| ml-for-ml replacement | Small absolute volumes mean even 50 mL errors are clinically significant in patients <20 kg | Document all fluid in/out in real time. Use infusion pumps for replacement fluid delivery. |
| Positive balance targeting | Children are more susceptible to hypovolemia; negative balance is poorly tolerated | Target slight positive fluid balance (+50–100 mL) in patients <20 kg unless contraindicated by cardiac/renal status. |
| Replacement fluid selection | Albumin 5% is standard; FFP required if coagulation factors are depleted | Use FFP for >1.5 plasma volume exchanges or if coagulopathy is present. Consider 4% albumin in neonates. |
| Pre-procedure hydration | Dehydrated children are at high risk for hypotension at procedure start | Ensure adequate hydration before starting. Consider 10 mL/kg NS bolus pre-procedure if clinically indicated. |
⚠️ Replacement Fluid Note: Albumin vs. FFP in Children
Albumin 5% is the preferred replacement fluid for most pediatric TPE procedures. However, FFP should be used (or added) when: (1) the procedure involves >1.5 plasma volumes, (2) the patient has a pre-existing coagulopathy, or (3) the indication itself involves coagulation factor deficiency (e.g., TTP — FFP is the only appropriate replacement fluid). In neonates, 4% albumin may be preferred over 5% to reduce osmotic load.
5 Hypothermia Prevention
Children have a significantly higher body surface area to volume ratio than adults. When blood passes through an extracorporeal circuit at room temperature, it loses heat rapidly. In small children, this can cause core body temperature to drop by 1–2°C during a single procedure, leading to hypothermia-induced coagulopathy, cardiac arrhythmias, and increased metabolic demand.
Blood Warmer Mandatory for All Patients <25 kg
A blood/fluid warmer must be placed on the return line for all pediatric patients under 25 kg. This is not optional. The warmer should be set to 37°C. Additionally, the procedure room should be warmed to at least 24°C, and the patient should be covered with warm blankets. For neonates and infants, a radiant warmer or warming mattress should be used throughout the procedure.
Hypothermia Prevention Bundle
| Intervention | Applies To | Standard |
|---|---|---|
| Blood/fluid warmer on return line | All patients <25 kg (mandatory); 25–40 kg (recommended) | Set to 37°C. Verify function before procedure start. |
| Warm procedure room | All pediatric patients | Room temperature ≥24°C during procedure. |
| Warm blankets | All pediatric patients | Cover all exposed body surface area not required for monitoring. |
| Radiant warmer / warming mattress | Neonates and infants (<12 months) | Use throughout procedure. Monitor skin temperature to avoid burns. |
| Temperature monitoring | All pediatric patients | Continuous core temperature monitoring (rectal or axillary). Alert threshold: <36.0°C. |
| Warm replacement fluids | Large-volume exchanges | Pre-warm albumin and FFP to 37°C before infusion when possible. |
6 Sedation & Behavioral Considerations
Young children and developmentally delayed patients may be unable to remain still during a 2–4 hour apheresis procedure. Movement disrupts the extracorporeal circuit, causes catheter dislodgement, and introduces air into the system. The decision to sedate must balance the risks of sedation against the risks of an uncontrolled procedure.
Sedation Decision Framework
| Patient Profile | Approach | Considerations |
|---|---|---|
| Cooperative child (≥6–7 yr, developmentally appropriate) | No sedation; distraction techniques | Child life specialist involvement; tablet/screen distraction; parental presence. |
| Young child (2–6 yr) or anxious patient | Light sedation (midazolam PO/IV) | Midazolam 0.05–0.1 mg/kg IV. Monitor respiratory status. Parental presence strongly recommended. |
| Infant or non-cooperative child | Moderate sedation or general anesthesia | Requires anesthesia team involvement. Airway management equipment at bedside. Continuous SpO₂ and ETCO₂ monitoring. |
| ICU patient (intubated/sedated) | Procedure during existing sedation | Coordinate with ICU team. Adjust sedation as needed. Monitor hemodynamics closely. |
ℹ️ Parental Presence
Parental presence during pediatric apheresis is strongly recommended by the Springer 2026 Concise Manual of Apheresis Therapy. A familiar caregiver significantly reduces procedure-related anxiety, reduces the need for sedation, and improves the child's ability to communicate symptoms (pain, tingling, nausea) to the clinical team. Prepare parents in advance with a clear explanation of what they will see during the procedure.
→ Pediatric-Specific Disease Indications
Most ASFA categories apply to both adults and children, but several conditions have pediatric-specific considerations — either because they predominantly affect children, because the evidence base is primarily pediatric, or because treatment protocols differ significantly from adults.
🧠 Anti-NMDAR Encephalitis
Most common autoimmune encephalitis in children. TPE is second-line after steroids + IVIg. A 2025 study of 73 pediatric patients (Zeng et al.) found 84% clinical improvement with combined immunotherapy including TPE. Timing is critical — initiate within 2 weeks of symptom onset.
🩸 Sickle Cell Disease (Pediatric)
RBC exchange for acute stroke and stroke prevention is ASFA Category I in children. Pediatric targets are often more aggressive: maintain HbS <30% for stroke prevention. All procedures require strict ECV calculation, fluid balance, and vascular access planning. Exchange transfusion is also used for acute chest syndrome and priapism.
🔥 Hemophagocytic Lymphohistiocytosis (HLH)
A life-threatening hyperinflammatory syndrome predominantly affecting children. TPE is used as a bridge to definitive therapy (HLH-94/2004 protocol, HSCT). A 2024 multicenter study found 72.7% overall survival in pediatric TPE-treated patients, with HLH having the highest mortality among all indications. ASFA Category III.
🫀 Kawasaki Disease (Refractory)
Refractory Kawasaki disease (failure of 2 IVIG doses) is an emerging pediatric indication for TPE. A 2023 case series reported successful use in children weighing <10 kg — one of the most challenging weight categories for apheresis. ASFA Category III. Particularly relevant for preventing coronary artery aneurysms.
🧬 MIS-C (Multisystem Inflammatory Syndrome)
Post-COVID hyperinflammatory syndrome in children. Not yet formally classified by ASFA. TPE is increasingly used as rescue therapy for severe, IVIG/steroid-refractory cases. Emerging evidence supports its use in cytokine storm management. See the dedicated MIS-C page for full clinical detail.
🍼 Neonatal Hemolytic Disease (HDFN)
Hemolytic Disease of the Fetus and Newborn due to maternal alloantibodies (anti-D, anti-K, etc.). Double-volume exchange transfusion (DVET) is the definitive treatment for severe neonatal hyperbilirubinemia and anemia. ASFA Category I. Requires specialized neonatal expertise and strict temperature/volume management.
🧪 Wilson Disease (Acute Liver Failure)
Acute liver failure from Wilson disease in children and young adults is a rare but rapidly fatal condition. TPE is used as a bridge to liver transplantation, removing copper-albumin complexes and inflammatory mediators. ASFA Category I for acute liver failure presentation.
🩺 MOGAD (Pediatric)
MOG antibody-associated disease has a higher incidence in children than adults. The 2025 Schwake et al. JNNP study included pediatric patients. The same timing principle applies: complete remission rates drop from 67% to 15% when TPE is delayed beyond 2 days. Pediatric MOGAD often presents as ADEM (acute disseminated encephalomyelitis).
→ Pediatric Pre-Procedure Safety Checklist
This checklist consolidates the five safety pillars into a single pre-procedure verification tool. All items should be confirmed before connecting the patient to the apheresis circuit.
- ECV Calculated: ECV% of TBV calculated using age-appropriate TBV formula. Decision documented: No prime / Albumin prime / pRBC prime.
- Circuit Primed (if required): Circuit primed with appropriate fluid (pRBCs or 5% albumin) if ECV >10% TBV. pRBC prime used if ECV >15% TBV.
- Vascular Access Confirmed: Catheter French size appropriate for patient weight. Flow rates tested and adequate before starting. No kinking or positional dependence.
- IV Calcium Ready: Calcium gluconate 10% infusion prepared and running (or ready to start) at procedure initiation. Dose: 1–2 mL/kg/hr. Ionized calcium baseline documented.
- Blood Warmer Installed (if <25 kg): Blood/fluid warmer on return line, set to 37°C, function verified. Room temperature ≥24°C. Warm blankets applied.
- Fluid Balance Plan Documented: Target fluid balance defined (positive/neutral/negative). Infusion pumps in use for replacement fluid delivery. Real-time tracking initiated.
- Sedation Plan Confirmed (if applicable): Sedation plan discussed with team. Appropriate monitoring in place (SpO₂, ETCO₂ if moderate sedation). Reversal agents available.
- Parental/Guardian Consent and Presence: Informed consent obtained. Parent/guardian briefed on procedure, expected duration, and what to watch for. Presence during procedure confirmed if desired.
- Emergency Medications Available: Calcium gluconate (IV bolus dose), epinephrine, diphenhydramine, and normal saline bolus drawn up or immediately available at bedside.
- Temperature Monitoring Active: Continuous core temperature monitoring in place. Alert threshold set at <36.0°C.
→ References
All references verified February 2026. DOIs and PubMed IDs confirmed against publisher records. Links open in a new tab.
- Eichinger K, Breu M, Renken M, Siegert S, Hilz E, Glatter S, et al. Complications of Therapeutic Plasma Exchange in Pediatric Neuroimmune Disorders. Children (Basel). 2025;12(11):1457. doi:10.3390/children12111457 — PubMed 41300575 Free PMC Article
- Sawada M. Apheresis in Children. In: The Concise Manual of Apheresis Therapy. Springer; February 2026. pp. 403–419. doi:10.1007/978-981-95-4864-4_41 [Springer]
- kidney.wiki. Therapeutic Apheresis: Vascular Access. Accessed February 2026. kidney.wiki/apheresis/apheresis-access/ [Free Access — Nephrology Education Resource]
- Connelly-Smith L, Alquist CR, Aqui NA, Hofmann JC, Klingel R, Onwuemene OA, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice — Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher. 2023;38(2):77–278. doi:10.1002/jca.22043 Free Full Text — PubMed 37017433
- Özkaya PY, Koç G, Ersayoğlu İ, Cebeci K, Özdemir HH, Karadas N, et al. Therapeutic plasma exchange in critically ill children: A single center experience. Ther Apher Dial. 2024;28(5):793–801. doi:10.1111/1744-9987.14141 Free PMC Article — PubMed 38747186 (Author corrected: first author is Özkaya PY)
- Hans R, Sharma RR, Marwaha N. Role of therapeutic apheresis in pediatric disorders. Transfus Apher Sci. 2016;55(3):338–343. doi:10.1016/j.transci.2016.10.001 — PubMed 27769650
- Meyer EK, Wong ECC. Pediatric therapeutic apheresis: a critical appraisal of evidence. Transfus Med Rev. 2016;30(4):213–220. doi:10.1016/j.tmrv.2016.07.001 — PubMed 27499017
- Kemper AR, Newman TB, Slaughter JL, Maisels MJ, Watchko JF, Downs SM, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022;150(3):e2022058859. doi:10.1542/peds.2022-058859 — PubMed 35927462 Open Access
- Jacobs JW, Booth GS, Adkins BD, Costa V, Raza S, Park YA, et al. When Strong Recommendations Rest on Weak Evidence: Lessons From Therapeutic Apheresis Guidelines. J Clin Apher. 2026;41(1):e70098. doi:10.1002/jca.70098 Open Access